This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Early Determination of Prognosis by Interim 3'-Deoxy-3'-18F-Fluorothymidine PET in Patients with Non-Hodgkin Lymphoma
- Oesophageal squamous cell carcinoma: relationship between fluorine-18 fludeoxyglucose positron emission tomography CT maximum standardised uptake value, metabolic tumour volume, and tumour, node and metastasis classification
- Metabolic Tumor Volume of [18F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Predicts Short-Term Outcome to Radiotherapy With or Without Chemotherapy in Pharyngeal Cancer
- Is There a Role for Positron Emission Tomography in Breast Cancer Staging?
- Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
- FDG-PET and Beyond: Molecular Breast Cancer Imaging
- [18F]Fluorodeoxyglucose Uptake by Positron Emission Tomography Predicts Outcome of Non-Small-Cell Lung Cancer
- Prospective Multicenter Study of Axillary Nodal Staging by Positron Emission Tomography in Breast Cancer: A Report of the Staging Breast Cancer With PET Study Group
- Pre-operative staging of invasive breast cancer with MR mammography and/or PET: boon or bunk?
- Whole-Body 18F-FDG PET and Conventional Imaging for Predicting Outcome in Previously Treated Breast Cancer Patients
- Impact of Whole-Body 18F-FDG PET on Staging and Managing Patients with Breast Cancer: The Referring Physician's Perspective
- 18Fluorodeoxyglucose Positron Emission Tomography to Detect Mediastinal or Internal Mammary Metastases in Breast Cancer
- A Tabulated Summary of the FDG PET Literature
- Is There a Role for FDG PET in the Diagnosis of Musculoskeletal Neoplasms?